Work

Abstract P2-16-13: Phase I dose escalation clinical trial of the PI3K inhibitor BKM120 and capecitabine (C) in metastatic breast cancer (MBC)

Year: 2013

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/0008-5472.sabcs13-p2-16-13

Authors: EC Dees, PK Marcom, A Snavely, J Noe, CK Anders, K Blackwell, G Kimmick, K Reeder-Hayes, D Rosenstein, CM Perou, LA Carey

Institutions: University of North Carolina at Chapel Hill, Duke Medical Center, UNC Lineberger Comprehensive Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2085769716

Cites:

Cited by: 1

Related to: 10